Online Public Access Catalog

Microbial infections and cancer therapy / (Record no. 316521)

MARC details
000 -LEADER
fixed length control field 06016cam a2200589Ii 4500
001 - CONTROL NUMBER
control field 9781351041904
003 - CONTROL NUMBER IDENTIFIER
control field FlBoTFG
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220412035804.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr cnu---unuuu
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 190223s2019 si ob 001 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency OCoLC-P
Language of cataloging eng
Description conventions rda
Transcribing agency OCoLC-P
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781351041898
Qualifying information electronic book
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1351041894
Qualifying information electronic book
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781351041904
Qualifying information electronic book
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1351041908
Qualifying information electronic book
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781351041874
Qualifying information electronic book
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1351041878
Qualifying information electronic book
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781351041881
Qualifying information electronic book
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1351041886
Qualifying information electronic book
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)1088341308
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC-P)1088341308
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number QR46
Item number .M53 2019
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 009000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 022090
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 071000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code TCB
Source bicssc
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.99/401
Edition number 23
245 00 - TITLE STATEMENT
Title Microbial infections and cancer therapy /
Statement of responsibility, etc. edited by Ananda M. Chakrabarty, Arsénio M. Fialho.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Singapore :
Name of producer, publisher, distributor, manufacturer Pan Stanford Publishing Pte. Ltd.,
Date of production, publication, distribution, manufacture, or copyright notice [2019]
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Cover; Half Title; Title Page; Copyright Page; Table of Contents; Preface; 1: Bifidobacterium as a Delivery System of Functional Genes for Cancer Therapy; 1.1 The Potential Superiority of Bifidobacterium as a Delivery System for Cancer Gene Therapy; 1.1.1 The Biological Features of Bifidobacterium Associated with Cancer Gene Therapy; 1.1.2 Endogenous Plasmids and Cloning Vectors in Bifidobacterium; 1.1.3 Expression Plasmids in Bifidobacterium for Cancer Gene Therapy; 1.1.3.1 Plasmid pBLES100; 1.1.3.2 Plasmid pGEX-1LamdaT; 1.1.3.3 Plasmids pBV220 and pBV22210
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 1.2 The Anticancer Mechanism of Bifidobacterium as an Oral Delivery System for Cancer Gene Therapy1.2.1 Oral Administration of Bifidobacterium Affects the Immune System; 1.2.2 Oral Administration of Bifidobacterium Modulates Gut Microbial Community; 1.2.3 Oral Administration of Bifidobacterium Affects Cancer Cell Signal Transduction; 1.3 The Application of Bifidobacterium as a Delivery System of Functional Genes for Cancer Therapy; 1.3.1 Bifidobacterium as a Delivery System of Functional Genes for Cancer Gene Therapy; 1.3.2 Bifidobacterium Combination with Other Fac tors for Synergy
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 1.3.2.1 Combination with radiation and chemotherapeutic drugs1.3.2.2 Combination with prebiotics; 1.3.2.3 Combination with trace element selenium; 1.3.3 The New Mutagenesis Strategies for Genetic Modification of Bifidobacterium; 1.3.3.1 Single-crossover plasmid insertion; 1.3.3.2 Double-crossover and double-crossover markerless gene deletion; 1.3.3.3 Homologous recombination mediated by a temperature-sensitive plasmid; 1.4 Future Prospects; 2: Therapy with Oncolytic Clostridium novyi-NT: From Mice to Men; 2.1 Targeted Therapies at the Tissue Level
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 2.2 Clostridia as Live Therapeutic Agents for Cancer Therapy2.3 C. novyt NT as a Live Therapeutic Agent for Cancer Therapy; 2.3.1 C. novyi; 2.3.2 C. novyi-NT; 2.4 Preclinical Studies: Toxicity Associated with C. novyi-NT Treatment; 2.5 Preclinical Studies: Therapeutic Effects; 2.6 Preclinical Studies: Combination Approaches for Optimized Efficacy; 2.7 From Bench to Bedside; 2.8 Clinical Studies: Canine Trial; 2.9 Clinical Studies: Phase I Human Trial; 2.10 Summaiy and Future Perspectives; 3: Genetic Engineering of Clostridial Strains for Cancer Therapy
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 3.1 Tumor Hypoxia and Necrosis: A Blessing in Disguise?3.2 Clostridia as Cancer-Fighting Agents; 3.2.1 Embodiment of Treatment; 3.2.1.1 Administration route and form; 3.2.1.2 Tumor colonization; 3.2.1.3 Mechanism of action; 3.2.1.4 Termination of treatment; 3.2.2 Limitations of Clostridial Oncolysis; 3.3 Genetic Engineering Approaches; 3.3.1 The Underpinning Science; 3.3.1.1 Genetic tools; 3.3.1.2 Strain selection; 3.3.2 Clostridial-Directed Enzyme Prodrug Therapy; 3.3.2.1 Cytosine deaminase; 3.3.2.2 Nitroreductases; 3.3.2.3 Carboxypeptidase G2; 3.3.3 Clostridial-Directed Antibody Therapy
500 ## - GENERAL NOTE
General note 3.3.3.1 Anti-hypoxia-inducible factor 1 alpha antibody
520 ## - SUMMARY, ETC.
Summary, etc. This book deals with the emerging concept that certain pathogenic bacteria and viruses, when infecting people with cancer, actively fight tumors, allowing their regression. Although such observations go back more than 100 years, use of specific bacterial strains, or viruses, usually genetically modified with known anticancer drugs, and their protein/peptide products, has gained ground in recent years, allowing significant cancer regression in clinical trials with stage III/IV cancer patients or even in pediatric brain tumor patients, often without any demonstration of toxicity. It is composed of 12 chapters written by pioneers in microbial, biotech, and cancer research and covers the emerging roles of various microorganisms and their products in cancer therapy. The book highlights the benefits of using conventional cancer treatments (such as chemo- and radiotherapies) with microbial-based therapies. Such combinatorial therapies have gained particular attention as a strategy to overcome drug resistance, and the readers of the book will discover their impact on fundamental research and promising results from clinical trials.
588 ## - SOURCE OF DESCRIPTION NOTE
Source of description note OCLC-licensed vendor bibliographic record.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Medical microbiology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cancer
General subdivision Treatment.
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element MEDICAL / Biotechnology
Source of heading or term bisacsh
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element MEDICAL / Infectious Diseases
Source of heading or term bisacsh
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element MEDICAL / Pharmacology
Source of heading or term bisacsh
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Fialho, Arsenio,
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Chakrabarty, Ananda M.,
Dates associated with a name 1938-
Relator term editor.
856 40 - ELECTRONIC LOCATION AND ACCESS
Materials specified Taylor & Francis
Uniform Resource Identifier <a href="https://www.taylorfrancis.com/books/9781351041904">https://www.taylorfrancis.com/books/9781351041904</a>
856 42 - ELECTRONIC LOCATION AND ACCESS
Materials specified OCLC metadata license agreement
Uniform Resource Identifier <a href="http://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf">http://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf</a>

No items available.

© 2022, Kenya National Library Service | Customized & Maintained by Uvumbuzi Center